IFN-γ在肿瘤免疫检查点抑制剂治疗中的研究进展

doi:10.11904/j.issn.1002-3070.2024.05.008

Abstract

Abstract: Immune checkpoint inhibitors(ICIs)mainly promote anti-tumor immunity by relieving tumor immune suppression.Interferon-γ(IFN-γ)plays an important role in increasing tumor antigen presentation,inducing immune cell infiltration,and directly inducing tumor cell apoptosis,becoming a key factor in improving the efficacy of immunotherapy.The abnormal signaling pathway of IFN-γ and its own effect on promoting tumor are the key mechanisms that trigger resistance to ICIs therapy.Immunotherapy,when combined with IFN-γ or IFN-γ inducers,can effectively restore the presentation ability of MHC-I,increase immune cell infiltration,and thus improve the efficacy of immunotherapy.In addition,domestic and foreign scholars have achieved certain therapeutic effects on clinical trials by normalizing the IFN-γ signaling pathway and combining ICIs with JAKi.This review mainly introduces the role of IFN-γ in the treatment of tumor ICIs,providing direction for potential treatment strategies to reverse ICIs resistance and further providing theoretical basis for clinical application.

Key words: IFN-γ, Cancer, Immune checkpoint inhibitors, Therapeutic resistance

CLC Number:

HE Jiaying, ZHU Jinli, JIA Kaixuan, YANG Peiying. Research progress of IFN-γ in the treatment of tumor immune checkpoint inhibitors[J]. Journal of Practical Oncology, 2024, 38(5): 330-335.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2024.05.008

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2024/V38/I5/330

References

1 Rui R,Zhou L,He S.Cancer immunotherapies:advances and bottlenecks[J].Front Immunol,2023,14:1212476.
2 Marei HE,Hasan A,Pozzoli G,et al.Cancer immunotherapy with immune checkpoint inhibitors(ICIs):potential,mechanisms of resistance,and strategies for reinvigorating T cell responsiveness when resistance is acquired[J].Cancer Cell Int,2023,23(1):64.
3 Gocher AM,Workman CJ,Vignali D.Interferon-gamma:teammate or opponent in the tumour microenvironment?[J].Nat Rev Immunol,2022,22(3):158-172.
4 Seiwert TY,Burtness B,Mehra R,et al.Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck(KEYNOTE-012):an open-label,multicentre,phase 1b trial[J].Lancet Oncology,2016,17(7):956-965.
5 Muro K,Chung HC,Shankaran V,et al.Pembrolizumab for patients with PD-L1-positive advanced gastric cancer(KEYNOTE-012):a multicentre,open-label,phase 1b trial[J].Lancet Oncology,2016,17(6):717-726.
6 Fehrenbacher L,Spira A,Ballinger M,et al.Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer(POPLAR):a multicentre,open-label,phase 2 randomised controlled trial[J].Lancet,2016,387(10030):1837-1846.
7 Reschke R,Gajewski TF.CXCL9 and CXCL10 bring the heat to tumors[J].Sci Immunol,2022,7(73):6509.
8 Reschke R,Enk AH,Hassel JC.Chemokines and cytokines in immunotherapy of melanoma and other tumors:from biomarkers to therapeutic targets[J].Int J Mol Sci,2024,25(12):6532.
9 Fang S,Xu T,Xiong M,et al.Role of immune response,inflammation,and tumor immune response-related cytokines/chemokines in melanoma progression[J].J Invest Dermatol,2019,139(11):2352-2358.
10 Baer C,Squadrito ML,Laoui D,et al.Suppression of microRNA activity amplifies IFN-gamma-induced macrophage activation and promotes anti-tumour immunity[J].Nat Cell Biol,2016,18(7):790-802.
11 Zhang Y,Ma S,Li T,et al.ILC1-derived IFN-gamma regulates macrophage activation in colon cancer[J].Biol Direct,2023,18(1):56.
12 Liu C,Chikina M,Deshpande R,et al.Treg cells promote the SREBP1-dependent metabolic fitness of tumor-promoting macrophages via repression of CD8(+)T cell-derived interferon-gamma[J].Immunity,2019,51(2):381-397.
13 Zhou F.Molecular mechanisms of IFN-gamma to up-regulate MHC class I antigen processing and presentation[J].Int Rev Immunol,2009,28(3-4):239-260.
14 Rimando JC,Chendamarai E,Rettig MP,et al.Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells[J].Blood,2023,141(14):1718-1723.
15 Kammertoens T,Friese C,Arina A,et al.Tumour ischaemia by interferon-gamma resembles physiological blood vessel regression[J].Nature,2017,545(7652):98-102.
16 Zhang Z,Zhang Y,Xia S,et al.Gasdermin E suppresses tumour growth by activating anti-tumour immunity[J].Nature,2020,579(7799):415-420.
17 Yu L,Huang K,Liao Y,et al.Targeting novel regulated cell death:ferroptosis,pyroptosis and necroptosis in anti-PD-1/PD-L1 cancer immunotherapy[J].Cell Prolif,2024,57(8):e13644.
18 Gao J,Shi LZ,Zhao H,et al.Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to Anti-CTLA-4 therapy[J].Cell,2016,167(2):397-404.
19 Overacre-Delgoffe AE,Chikina M,Dadey RE,et al.Interferon-gamma drives Treg fragility to promote anti-tumor immunity[J].Cell,2017,169(6):1130-1141.
20 Shin DS,Zaretsky JM,Escuin-Ordinas H,et al.Primary resistance to PD-1 blockade mediated by JAK1/2 mutations[J].Cancer Discov,2017,7(2):188-201.
21 Zaretsky JM,Garcia-Diaz A,Shin DS,et al.Mutations associated with acquired resistance to PD-1 blockade in melanoma[J].N Engl J Med,2016,375(9):819-829.
22 Wong CW,Huang YY,Hurlstone A.The role of IFN-gamma-signalling in response to immune checkpoint blockade therapy[J].Essays Biochem,2023,67(6):991-1002.
23 Song M,Ping Y,Zhang K,et al.Low-dose IFNgamma induces tumor cell stemness in tumor microenvironment of non-small cell lung cancer[J].Cancer Res,2019,79(14):3737-3748.
24 Benci JL,Xu B,Qiu Y,et al.Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade[J].Cell,2016,167(6):1540-1554.
25 Stifter K,Krieger J,Ruths L,et al.IFN-gamma treatment protocol for MHC-I(lo)/PD-L1(+)pancreatic tumor cells selectively restores their TAP-mediated presentation competence and CD8 T-cell priming potential[J].J Immunother Cancer,2020,8(2):e000692.
26 Zhang M,Huang L,Ding G,et al.Interferon gamma inhibits CXCL8-CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer[J].J Immunother Cancer,2020,8(1):e000308.
27 Zibelman M,MacFarlane AT,Costello K,et al.A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors[J].Nat Commun,2023,14(1):4513.
28 Garris CS,Arlauckas SP,Kohler RH,et al.Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12[J].Immunity,2018,49(6):1148-1161.
29 Greaney SK,Algazi AP,Tsai KK,et al.Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses[J].Cancer Immunol Res,2020,8(2):246-254.
30 Algazi AP,Twitty CG,Tsai KK,et al.Phase II trial of IL-12 plasmid transfection and PD-1 blockade in immunologically quiescent melanoma[J].Clin Cancer Res,2020,26(12):2827-2837.
31 Toney NJ,Gatti-Mays ME,Tschernia NP,et al.Immune correlates with response in patients with metastatic solid tumors treated with a tumor targeting immunocytokine NHS-IL12[J].Int Immunopharmacol,2023,116:109736.
32 Du W,Hua F,Li X,et al.Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation[J].Cancer Discov,2021,11(7):1826-1843.
33 Zhang Y,Wang M,Ye L,et al.HKDC1 promotes tumor immune evasion in hepatocellular carcinoma by coupling cytoskeleton to STAT1 activation and PD-L1 expression[J].Nat Commun,2024,15(1):1314.
34 Du WY,Masuda H,Nagaoka K,et al.Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice[J].Gastric Cancer,2024,27(5):971-985.
35 Lynce F,Stevens LE,Li Z,et al.TBCRC 039:a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer[J].Breast Cancer Res,2024,26(1):20.
36 Munster P,Iannotti N,Cho DC,et al.Correction:combination of itacitinib or parsaclisib with pembrolizumab in patients with advanced solid tumors:a phase I study[J].Cancer Res Commun,2024,4(3):785.
37 Mathew D,Marmarelis ME,Foley C,et al.Combined JAK inhibition and PD-1 immunotherapy for non -small cell lung cancer patients[J].Science,2024,384(6702):1314.
38 Angelicola S,Ruzzi F,Landuzzi L,et al.IFN-gamma and CD38 in hyperprogressive cancer development[J].Cancers(Basel),2021,13(2):309.
39 Liang X,Gao H,Xiao J,et al.Abrine,an IDO1 inhibitor,suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma[J].Front Immunol,2023,14:1185985.
40 Long GV,Dummer R,Hamid O,et al.Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma(ECHO-301/KEYNOTE-252):a phase 3,randomised,double-blind study[J].Lancet Oncol,2019,20(8):1083-1097.
41 Necchi A,Van der Heijden MS,Trukhin D,et al.Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma:results from the ECHO-307/KEYNOTE-672 study[J].BMC Cancer,2024,23(Suppl 1):1252.
42 Labadie BW,Bao R,Luke JJ.Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis[J].Clin Cancer Res,2019,25(5):1462-1471.
43 Wong CW,Evangelou C,Sefton KN,et al.PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNgamma-driven acquired resistance in preclinical cancer models[J].Nat Commun,2023,14(1):5983.
44 Fenton SE,Zannikou M,Ilut L,et al.Targeting ULK1 decreases IFNgamma-mediated resistance to immune checkpoint inhibitors[J].Mol Cancer Res,2023,21(4):332-344.

[1]	CHEN Maosen, WEN Hongmei, SHI Qingping, SHAO Ying, TANG Xian, REN Siying, CHEN Yang. Analysis of the incidence and mortality of cervical cancer in cancer registration areas of Yunnan province in 2020 and the trend from 2012 to 2020 [J]. Journal of Practical Oncology, 2024, 38(6): 355-360.
[2]	WANG Meixian, ZHENG Keqin, YU Qiuli, WEN Hongmei, YANG Cangjiang, REN Siying. Analysis of the esophageal cancer incidence and mortality in Yunnan province in 2020 and the trend from 2012 to 2020 [J]. Journal of Practical Oncology, 2024, 38(6): 361-366.
[3]	XU Xianhui, CHEN Yang, ZHU Yunfang, LI Mingsong, WEN Hongmei. Incidence and mortality of lung cancer in cancer registration areas of Yunnan province in 2020 and the trends from 2012 to 2020 [J]. Journal of Practical Oncology, 2024, 38(6): 367-371.
[4]	KONG Hongqian, DONG Juan, WEN Hongmei, SHAO Ying, CHENG Huirong, YU Qiuli. Analysis of gastric cancer incidence and mortality in cancer registration areas of Yunnan province in 2020 and the trends from 2012 to 2020 [J]. Journal of Practical Oncology, 2024, 38(6): 372-376.
[5]	FAN Yunyuan, TANG Xian, WEN Hongmei, SHAO Ying, SHI Jingyin, ZHANG Shuangquan. Analysis of the incidence and mortality of liver cancer in cancer registration areas of Yunnan province in 2020 and the trend from 2012 to 2020 [J]. Journal of Practical Oncology, 2024, 38(6): 377-382.
[6]	DONG Juan, KONG Hongqian, WEN Hongmei, SHI Qingping, SHAO Ying. Analysis of the prostate cancer incidence and mortality in cancer registration areas of Yunnan province in 2020 and the trend from 2012 to 2020 [J]. Journal of Practical Oncology, 2024, 38(6): 383-387.
[7]	YANG Xiaobin, WANG Junping. Effects of BTg-3 on proliferation,invasion,migration and Akt/GSK-3β/β-catenin signaling pathway of liver cancer cells [J]. Journal of Practical Oncology, 2024, 38(6): 410-416.
[8]	LI Qun, SHI Hanping, YANG Liuqing. Nutritional therapy for cancer patients [J]. Journal of Practical Oncology, 2024, 38(6): 417-420.
[9]	CHEN Xingyan, LI Xue, FU Qiang. Research progress of RNA methylation in lung cancer [J]. Journal of Practical Oncology, 2024, 38(6): 421-426.
[10]	CHEN Maosen, CHEN Yang, SHI Qingping, SHAO Ying, TANG Xian, REN Siying, WEN Hongmei. Analysis of the current status of cancer incidence and mortality in Yunnan province in 2020 [J]. Journal of Practical Oncology, 2024, 38(5): 283-288.
[11]	ZHAO Qianwen, SHE Xin, GENG Lijun, PENG Danli, LIU Shanshan. Age-period-cohort model and prediction of the incidence trend of gastric cancer in China from 1990 to 2021 [J]. Journal of Practical Oncology, 2024, 38(5): 289-294.
[12]	SU Feng, LIANG Lei, DENG Ying, ZHANG Tonglei, WANG Yanping. Analysis of the epidemic characteristics and trends of cancer in Ankang city,Shaanxi province from 2016 to 2020 [J]. Journal of Practical Oncology, 2024, 38(5): 300-305.
[13]	HAO Huiting, ZHAO Huijuan, XU Qiaohui. Expression and clinical significance of hypermethylated in cancer 1 in non-small cell lung cancer [J]. Journal of Practical Oncology, 2024, 38(5): 306-312.
[14]	ZHANG Yuqing, JING Jing, LIU Zhaoliang, AN Jing, AN Weiwei. The alternative splicing event of MZB1 is a potential biomarker of drug resistance in endocrine therapy of breast cancer [J]. Journal of Practical Oncology, 2024, 38(5): 313-322.
[15]	YANG Minye, XIAN Tongcheng, LIU Jingjian, BIE Jun, WANG Jie, LUO Yi. The expression of IL-23 in breast cancer tissues and its correlation with clinicopathological characteristics [J]. Journal of Practical Oncology, 2024, 38(5): 323-329.

Research progress of IFN-γ in the treatment of tumor immune checkpoint inhibitors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments